Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly

References

• Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 26,60–69 (1995).
   PubMed Web of Science ®Google Scholar
• Staessen J, Amery A, Fagard R Editorial review: isolated systolic hypertension in the elderly. J. Hypertens. 8,393–405 (1990).
   PubMed Web of Science ®Google Scholar
• Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the health survey for England 1998. Hypertension 38,827–832 (2001).
   PubMed Web of Science ®Google Scholar
• Kannel WB. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 20,277–286 (2003).
   PubMed Web of Science ®Google Scholar
• Fagard RH. Epidemioloy of hypertension in the elderly. Am. J. Geriat. Cardiol. 11, 23–28 (2002).
   Google Scholar
• Mourad JJ, Blacher J, Blin P et al. Conventional antihypertensive drug therapy does not prevent the increase of pulse pressure with age. Hypertension 38, 958–961 (2001).
   PubMedGoogle Scholar
• Sulbaran TA, Silva ER, Maestra G. Isolated systolic hypertension: a new challenge in medicine. J. Hum. Hypertens. 16, S44—S47 (2002).
   Google Scholar
• Martins D, Nelson K, Pan D et al. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J. Gend Specif: Med 4,10–13 (2001).
   PubMedGoogle Scholar
• Franklin SS, Larson MG, Khan SA et al Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103, 1245–1249 (2001).
   PubMed Web of Science ®Google Scholar
• •Epidemiological study showing that with increasing age there is a gradual shift from diastolic to systolic and then to pulse pressure as a predictor of coronary heart disease risk. The strength of the study is the large number of subjects (6500) in a wide age range (20–79 years) with a 20-year follow-up.
   Google Scholar
• Birkenhäger WH, Staessen JA, Gasowski J et al Effects of antihypertensive treatment on end points in the diabetic patients randomized in the Systolic hypertension in Europe (Syst-Eur) trial. J. 1VephroL 13, 232–237 (2000).
   Google Scholar
• Mitchell GF, Moye LA, Braunwald E et al Sphygrnomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 96,4254 4260 (1997).
   Google Scholar
• Safar ME, Blacher J, Pannier B et al Central pulse pressure and mortality in end-stage renal disease. Hypertension 39,735–738 (2002).
   PubMed Web of Science ®Google Scholar
• •Provides the first direct evidence that in patients with end-stage renal disease, the carotid pulse pressure level and the disappearance of pulse pressure amplification are strong independent predictors of all-cause (including cardiovascular) mortality.
   Google Scholar
• Blacher J, Staessen JA, Girerd X et al Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med 160,1085–1089 (2000).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, O'Brien ET et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am. J. Hypertens. 15,835–843 (2002).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG et al Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355,865–872 (2000).
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis estimates the risk fortotal mortality and cardiovascular events in patients with isolated systolic hypertension. In addition, this article shows that antihypertensive treatment reduces cardiovascular risk in elderly patients with isolated systolic hypertension.
   Google Scholar
• Asmar R, Safavian A, Tual JL et al. Arterial and cardiac changes in hypertension in the elderly. Blood Press. Suppl. 3,31–37 (1995).
   PubMedGoogle Scholar
• Schocken DD, Roth GS. Reduced 13-adrenergic receptor concentrations in ageing man. Nature 267,856–858 (1977).
   PubMed Web of Science ®Google Scholar
• Thompson J, Khalil RA. Gender differences in the regulation of vascular tone. Clin. Exp. Pharmacol. Physiol. 30, 1–15 (2003).
   PubMed Web of Science ®Google Scholar
• Heintz B, Dorr R, Gillessen T et al. Do arterial endothelin-1 levels affect local arterial stiffness? Am. Heart J. 126, 987–989 (1993).
   PubMedGoogle Scholar
• Hallock P, Benson IC. Studies on the elastic properties of human isolated aorta. J. Clin. Invest. 16,595–602 (1937).
   PubMedGoogle Scholar
• M'Buyamba-Kabangu JR, Fagard R, Lijnen P et al. Blood pressure and urinary cations in urban Bantu of Zaire. Am. J. Epidemiol. 124,957–968 (1986).
   PubMedGoogle Scholar
• Liao D, Arnett DK, Tyroler HA et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 34,201–206 (1999).
   PubMed Web of Science ®Google Scholar
• Benetos A, Okuda K, Lajemi M et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 37,381–385 (2001).
   PubMed Web of Science ®Google Scholar
• Aviv A, Aviv H. Reflections on telomeres, growth, aging, and essential hypertension. Hypertension 29, 1067–1072 (1997).
   PubMedGoogle Scholar
• de Lange T, Shiue L, Myers RI\4 et al. Structure and variability of human chromosome ends. Mol. Cell. Biol. 10, 518–527 (1990).
   PubMed Web of Science ®Google Scholar
• Allsopp RC, Vaziri H, Patterson C et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. Nati Acad. Sci. USA 89,10114–10118 (1992).
   PubMed Web of Science ®Google Scholar
• Aviv A. Pulse pressure and human longevity. Hypertension 37,1060–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. Pathophysiology, screening and treatment. Arch. Intern. Med. 158,1301–1306 (1998).
   PubMed Web of Science ®Google Scholar
• Xu D, Neville R, Finkel T Homocysteine accelerates endothelial cell senescence. FEBS Lett. 470,20–24 (2000).
   PubMed Web of Science ®Google Scholar
• Mark AL, Correia M, Morgan DA et al. State-of-the-art-lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 33,537–541 (1999).
   PubMed Web of Science ®Google Scholar
• Lehman ED, Hopkins KD, Gosling RG.Aortic compliance measurements using Doppler ultrasound: in vivo biochemical correlates. Ultrasound Med. Biol. 19, 683–710 (1993).
   PubMedGoogle Scholar
• Farrar DJ, Bond MG, Riley WA et al. Anatomic correlates of aortic pulse wave velocity and carotid artery elasticity during atherosclerosis progression and regression in monkeys. Circulation 83,1754–1763 (1991).
   PubMed Web of Science ®Google Scholar
• Mahmud A, Feely J. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 41,183–187 (2003).
   PubMed Web of Science ®Google Scholar
• Prisco D, Fedi S, Brunelli T et al. The influence of smoking on von Willebrand factor is already manifest in healthy adolescent females: the Floren-Teen (Florence Teenager) Study. Int. J. Clin. Lab. Res. 29, 150–154 (1999).
   Google Scholar
• Winniford MD. Smoking and cardiovascular function. J. Hypertens. 9\(Suppl. 5), S17—S23 (1990).
   Google Scholar
• Wiltshire EJ, Gent R, Hirte C et al. Endothelial dysfunction relates to folate status in children and adolescents with Type 1 diabetes. Diabetes 51,2282–2286 (2002).
   PubMedGoogle Scholar
• Larsen ML, Horder M, Mogensen ER Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J. Med. 323,1021–1025 (1990).
   PubMed Web of Science ®Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J. Med. 338, 1042–1050 (1998).
   PubMed Web of Science ®Google Scholar
• Bortolotto LA, Safar ME, Billaud E et al. Plasma homcysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 34,837–842 (1999).
   PubMed Web of Science ®Google Scholar
• van Guldener C, Lambert J, ter Wee PM et al. Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. Clin. Nephrol 53,33–41 (2000).
   PubMed Web of Science ®Google Scholar
• van Dijk RA, Rauwerda JA, Steyn M et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 21, 2072–2079 (2001).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension—European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Pickering TG, Coats A, Mallion JM et al. Task Force V: white-coat hypertension. Blood Press. Mona 4,333–341 (1999).
   PubMedGoogle Scholar
• Fagard RH, Staessen JA, Thijs L et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 102,1139–1144 (2000).
   PubMed Web of Science ®Google Scholar
• Somes GW, Pahor M, Shorr RI et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch. Intern. Med. 159,2004–2009 (1999).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomized, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350,757–764 (1997).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Med. Assoc. 265,3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the USA. N Engl J. Med. 345, 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that most cases ofuncontrolled hypertension in the USA consist of isolated, mild systolic hypertension in older adults.
   Google Scholar
• Alam MG, Barn i YM. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am. J. Hypertens. 16,140–143 (2003).
   PubMed Web of Science ®Google Scholar
• Fagard RH, Van den Enden M. Treatment and blood pressure control in isolated systolic hypertension vs. diastolic hypertension in primary care. J. Hum. Hypertens. 17,681–687 (2003).
   PubMedGoogle Scholar
• Franldin SS, Jacobs MJ, Wong ND et al Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Analysis based on National Health And Nutrition Examination Survey (NHANES) III. Hypertension 37,869–874 (2001).
   PubMedGoogle Scholar
• Thijs L, Staessen JA, Beleva S et al How well can blood pressure be controlled? Progress report on the Systolic hypertension in Europe follow-up study (Syst-Eur 2). Curr. Control Trials Cardiovasc. Med 2,298–306 (2001).
   PubMedGoogle Scholar
• Liu L, Wang JG, Gong L et al Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst-China) collaborative group. J. Hypertens. 16(12 Pt 1), 1823–1829 (1998).
   PubMedGoogle Scholar
• Staessen JA, Thijs L, Birkenhäger WH et al Update on the Systolic hypertension in Europe (Syst-Eur) trial. Hypertension 33, 1476–1477 (1999).
   PubMedGoogle Scholar
• Voyaki SM, Staessen JA, Thijs L et al Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J. Hypertens. 19, 511–519 (2001).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Arch. Intern. Med 158,1681–1691 (1998).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard RH et al Calcium-channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 32,410–416 (1998).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340, 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R et al, and the Systolic hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertension therapy on outcome in the Systolic hypertension in Europe trial. J. Hypertens. 22,847–857 (2004).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al Prevention of dementia in randomized double-blind placebo-controlled Systolic hypertension in Europe (Syst-Eur) trial. Lancet 352,1347–1351 (1998).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al The prevention of dementia with antihypertensive treatment. New evidence from the Systolic hypertension in Europe (Syst-Eur) study. Arch. Intern. Med 162,2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Bulpitt C, Boissel JP et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet 353, 793–796 (1999).
   PubMed Web of Science ®Google Scholar
• Bulpitt CJ, Beckett NS, Cooke J et al. Results of the pilot study for the hypertension in the very elderly trial. J. Hypertens. 21,2409–2417 (2003).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahltif B, Devereux RB et al. Effects of losartan on cardiovasclar morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For End point reduction (LIFE) substudy. J. Am. Med. Assoc. 288, 1491–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang J-G, Thijs L Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358, 1305–1315 (2001).
   PubMed Web of Science ®Google Scholar
• •Meta-regression analysis shows that the benefits of antihypertensive therapy largely depend on blood pressure lowering. This paper could not confirm the hypothesis that newer antihypertensive drugs influence cardiovascular prognosis over and beyond their blood-pressure lowering effects.
   Google Scholar